Amid a backlash against foreign investors, some executives are banned from leaving the country
The Camry, last overhauled for the 2011 model year, just got another face-lift
Laws require companies to pay state taxes on sheltered profits
Financial filings reveal the pay package Henrique de Castro received upon exit from the company.
Wal-Mart's new money transfers shows how the retailer can use its reach to push down costs
Skipping Rocks Lab develops a green alternative to all that plastic
Alessandro Borgognone wooed Japanese chef Daisuke Nakazawa to open the four-star New York eatery
Administrators quashed their food delivery service. Now they're focusing on other colleges
Prices are low, but there’s plenty of red tape
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."